There is a strong association between TP53 mutations and hepatocellular carcinoma (HCC). According to the Catalog of Somatic Mutations in Cancer (COSMIC) database, 30% of all HCC have a mutation in this gene, being ranked first in terms of mutation frequency for this disease.

Apr 2, 2007 · Multiple genetic and epigenetic changes are involved in the molecular pathogenesis of HCC, for example, somatic mutations in the p53 tumor suppressor gene (TP53) and the activation of the WNT signal transduction pathway.

Apr 2, 2007 · Multiple genetic and epigenetic changes are involved in the molecular pathogenesis of HCC, for example, somatic mutations in the p53 tumor suppressor gene (TP53) and the activation of the WNT...

Jul 27, 2023 · TP53 mutation and c-MET activation are frequent events in human HCCs. Here, we discovered that the simultaneous mutations in TP53 and activation of c-MET occur in ~20% of human HCCs, and these...

TP53 mutation is the most common mutation in hepatocellular carcinoma (HCC), and it affects the progression and prognosis of HCC. We investigated how TP53 mutation regulates the HCC immunophenotype and thus affects the prognosis of HCC.

Jan 29, 2025 · In this study, we investigated the clinical implications of TERTpm, TP53m, and their co-occurrence in 50 HCC tissue samples using the next-generation sequencing (NGS) technology. We identified...

Here we present a comprehensive review evaluating somatic mutations in TP53 and CTNNB1 genes in HBV- and HCV-related HCCs. Moreover, we report the mutational analysis of TP53 (exons 4-9) and CTNNB1 (exon 3) as well as PIK3CA (exon 9) genes in HCC from Southern Italy.

Hepatocellular carcinoma (HCC) is commonly associated with mutation of the TP53 gene and heterogeneity in immune cell content. However, TP53 mutation-associated immunotype of HCC has not been reported yet.

TP53 mutation is the most common genetic variation type in Hepatocellular carcinoma (HCC). We aim to illustrate the landscape of genomic alterations and TP53 mutation related and directly regulated lncRNA prognosis markers.

Mar 22, 2025 · TP53 and CTNNB1 mutation are the main mutational characteristics of glycan-HCC and lipid-HCC. Previous studies have reported that TP53 mutations are involved in a number of metabolic regulatory pathways, such as the balance of glycolysis and oxidative phosphorylation, limiting the production of reactive oxygen species, and contributing to the ...